Page last updated: 2024-09-05

sorafenib and tegafur

sorafenib has been researched along with tegafur in 20 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(tegafur)
Trials
(tegafur)
Recent Studies (post-2010) (tegafur)
6,5207305,2515,8921,4332,088

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (10.00)29.6817
2010's16 (80.00)24.3611
2020's2 (10.00)2.80

Authors

AuthorsStudies
Von Hoff, DD1
Hampton, T1
Kerbel, RS; Lee, CR; Man, S; Tang, TC; Xu, P1
Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC1
Baba, S; Kinoshita, M; Kurita, Y; Kyono, Y; Mugiya, S; Ozono, S; Takayama, T1
Homma, Y; Kaneko, T; Matsushima, H; Morimoto, H; Tsuzaka, Y1
Emmenegger, U; Francia, G; Hashimoto, K; Kerbel, RS; Man, S; Tang, TC; Xu, P1
Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW1
Katsahian, S; O'Quigley, J; Zohar, S1
Eto, M; Inokuchi, J; Kiyoshima, K; Kuroiwa, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A1
Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS1
Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY1
Cai, JP; Hao, XY; Hou, X; Lai, YR; Liang, LJ; Yin, XY; Zhai, JM; Zhang, LJ1
Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y1
Arai, K; Chiba, T; Kanai, F; Kaneko, S; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O1
Hu, X; Li, Q; Li, Y; Liang, R; Liao, S; Liao, X; Lin, Y; Liu, Z; Lv, Y; Yuan, C; Zhang, J1
Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y1
Ding, X; Li, H; Zhang, Z; Zhou, G; Zhou, Z1
Nakamura, T; Sakamoto, K; Takada, Y; Tamura, K; Tohyama, T; Wakisaka, H; Watanabe, J1
Akutsu, N; Hirano, T; Ishigami, K; Kawakami, Y; Nakase, H; Numata, Y; Sasaki, S; Wagatsuma, K1

Reviews

2 review(s) available for sorafenib and tegafur

ArticleYear
What's new in pancreatic cancer treatment pipeline?
    Best practice & research. Clinical gastroenterology, 2006, Volume: 20, Issue:2

    Topics: Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cancer Vaccines; Cetuximab; Cyclic N-Oxides; Deoxycytidine; Drug Combinations; Gastrins; Gemcitabine; Humans; Niacinamide; Oxonic Acid; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Tegafur; Tumor Necrosis Factor-alpha

2006
Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review.
    World journal of surgical oncology, 2020, May-28, Volume: 18, Issue:1

    Topics: Allografts; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Drug Combinations; End Stage Liver Disease; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pharyngeal Neoplasms; Pharynx; Positron Emission Tomography Computed Tomography; Sorafenib; Tegafur; Treatment Outcome

2020

Trials

6 trial(s) available for sorafenib and tegafur

ArticleYear
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
    Journal of hepatology, 2010, Volume: 53, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tegafur; Uracil

2010
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
    Journal of hepatology, 2011, Volume: 55, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Feasibility Studies; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Sorafenib; Tegafur; Uracil; Young Adult

2011
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Treatment Outcome

2012
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Oxonic Acid; Patient Compliance; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tegafur; Treatment Outcome

2014
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Prospective Studies; Sorafenib; Tegafur

2014
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug Combinations; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome

2015

Other Studies

12 other study(ies) available for sorafenib and tegafur

ArticleYear
Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
    JAMA, 2007, Jul-18, Volume: 298, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials, Phase III as Topic; Drug Combinations; Head and Neck Neoplasms; Humans; Liver Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Tegafur

2007
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Cyclophosphamide; Doxorubicin; Female; Humans; Injections, Subcutaneous; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Tegafur; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays

2010
Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.
    International journal of clinical oncology, 2011, Volume: 16, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Combinations; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Leukocytosis; Male; Medical Futility; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur

2011
[Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Tomography, X-Ray Computed; Uracil

2010
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Time Factors; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays

2010
An approach to meta-analysis of dose-finding studies.
    Statistics in medicine, 2011, Jul-30, Volume: 30, Issue:17

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Humans; Maximum Tolerated Dose; Meta-Analysis as Topic; Middle Aged; Models, Statistical; Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Tegafur

2011
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Female; Fluorouracil; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; RNA, Messenger; Sorafenib; Tegafur; Thymidylate Synthase

2011
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-15, Volume: 18, Issue:14

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Sorafenib; Tegafur; Treatment Outcome

2012
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Oxonic Acid; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Tegafur; Thymidylate Synthase

2013
Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
    Die Pharmazie, 2014, Volume: 69, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome

2014
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
    Anti-cancer drugs, 2016, Volume: 27, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Statistical; Niacinamide; Oxonic Acid; Phenylurea Compounds; Random Allocation; Sorafenib; Tegafur; Xenograft Model Antitumor Assays

2016
A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases.
    Clinical journal of gastroenterology, 2022, Volume: 15, Issue:5

    Topics: Carcinoma, Hepatocellular; Drugs, Investigational; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Skull; Sorafenib; Tegafur

2022